Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 11, Issue , 2017, Pages S209-S216

  Mahfood Haddad, Toufik ^a   Hamdeh, Shadi ^b   Kanmanthareddy, Arun ^a   Alla, Venkata M ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

BIBLIOGRAPHIC DATABASE; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DISEASE ASSOCIATION; FOLLOW UP; HEART DEATH; HUMAN; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; COMPLICATION;

CARDIOVASCULAR DISEASES; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85010653573     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2016.12.033     Document Type: Review

References (29)

1. Younossi, Z.M., Stepanova, M., Afendy, M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the united states from 1988 to 2008. Clin. Gastroenterol. Hepatol. 9:6 (2011), 524–530 e1; quiz e60.
2. Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34:3 (2011), 274–285.
3. Liu, H., Lu, H.Y., Nonalcoholic fatty liver disease and cardiovascular disease. World J. Gastroenterol. 20:26 (2014), 8407–8415.
4. Lankarani, K.B., Mahmoodi, M., Lotfi, M., et al. Common carotid intima-media thickness in patients with non-alcoholic fatty liver disease: a population-based case-control study. Korean J. Gastroenterol. 62:6 (2013), 344–351.
5. Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 49:4 (2008), 608–612.
6. Vilar, C.P., Cotrim, H.P., Florentino, G.S., et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Rev. Assoc. Med. Bras. 59:3 (2013), 290–297.
7. Ampuero, J., Gallego-Duran, R., Romero-Gomez, M., Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev. Esp. Enferm. Dig. 107:1 (2015), 10–16.
8. Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:15 (2000), 2008–2012.
9. Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
10. Wells, G., Shea, B., O'connell, D., et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2000.
11. Hamaguchi, M., Kojima, T., Takeda, N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 13:10 (2007), 1579–1584.
12. Wong, V.W., Wong, G.L., Yip, G.W., et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60:12 (2011), 1721–1727.
13. Lazo, M., Hernaez, R., Bonekamp, S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ, 343, 2011, d6891.
14. Stepanova, M., Younossi, Z.M., Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin. Gastroenterol. Hepatol. 10:6 (2012), 646–650.
15. El Azeem, H.A., Khalek, e.A., El-Akabawy, H., Naeim, H., Khalik, H.A., Alfifi, A.A., Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J. Saudi Heart Assoc. 25:4 (2013), 239–246.
16. Fracanzani, A.L., Tiraboschi, S., Pisano, G., et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 246 (2016), 208–213.
17. Clark, J.M., Brancati, F.L., Diehl, A.M., Nonalcoholic fatty liver disease. Gastroenterology 122:6 (2002), 1649–1657.
18. Dunn, W., Xu, R., Wingard, D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am. J. Gastroenterol. 103:9 (2008), 2263–2271.
19. Schindhelm, R.K., Dekker, J.M., Nijpels, G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the hoorn study. Atherosclerosis 191:2 (2007), 391–396.
20. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american gastroenterological association, american association for the study of liver diseases, and american college of gastroenterology. Gastroenterology 142:7 (2012), 1592–1609.
21. Misra, V.L., Khashab, M., Chalasani, N., Nonalcoholic fatty liver disease and cardiovascular risk. Curr. Gastroenterol. Rep. 11:1 (2009), 50–55.
22. Kim, D., Choi, S.Y., Park, E.H., et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56:2 (2012), 605–613.
23. Hansson, G.K., Inflammation atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352:16 (2005), 1685–1695.
24. Rajappa, M., Goswami, B., Balasubramanian, A., Chakraborty, B., Kumar, S., Interplay between inflammation and hemostasis in patients with coronary artery disease. Indian J. Clin. Biochem. 30:3 (2015), 281–285.
25. Schror, K., Huber, K., Platelets, inflammation and anti-inflammatory drugs in ACS and CAD. Thromb. Haemost. 114:3 (2015), 446–448.
26. Paoletti, R., Gotto, A.M., Hajjar, D.P. Jr., Inflammation in atherosclerosis and implications for therapy. Circulation 109:23 Suppl. 1 (2004), III20–III26.
27. Hui, J.M., Hodge, A., Farrell, G.C., Kench, J.G., Kriketos, A., George, J., Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40:1 (2004), 46–54.
28. Haukeland, J.W., Damas, J.K., Konopski, Z., et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44:6 (2006), 1167–1174.
29. Farrell, G.C., Larter, C.Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43:2 Suppl. 1 (2006), S99–S112.